The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,288.00
Bid: 12,286.00
Ask: 12,290.00
Change: 170.00 (1.40%)
Spread: 4.00 (0.033%)
Open: 12,244.00
High: 12,384.00
Low: 12,228.00
Prev. Close: 12,118.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GLOBAL MARKETS-Silver jumps, stocks slide as social trading roils market

Fri, 29th Jan 2021 21:32

(Adds close of U.S. markets)

* Silver prices rise on social media speculation

* J&J falls as vaccine disappoints

* Bitcoin jumps 14% after Elon Musk mention

* Treasury yields rise after inflation data

By Herbert Lash and Carolyn Cohn

NEW YORK/LONDON, Jan 29 (Reuters) - Silver prices jumped and
global equity markets sank on Friday amid a growing battle on
Wall Street between hedge funds and retail investors, while a
dispute over COVID-19 vaccine supply in Europe cooled risk
appetite.

Disappointing vaccine data from Johnson & Johnson
also hurt sentiment but the assault of retail traders using
online forums to force hedge funds to reverse short positions -
bets that stocks will fall - kept the market on edge.

Shares of GameStop Corp and AMC Entertainment
Holdings Inc surged again after Robinhood and
Interactive Brokers said they planned to ease restrictions after
imposing buying halts on Thursday.

GameStop soared 67.9% to $325 a share, five times its
closing price a week ago Friday, and AMC gained 53.7%, both in
heavy trade. AMC was one of the most active stocks on the New
York Stock Exchange. Volume on U.S. exchanges was 16.83 billion
shares, up from the 10.6 billion average in the fourth quarter.

Silver rallied and was up 2% at $26.90 an ounce,
taking gains to almost 10% since messages began to circulate on
Reddit early Thursday urging retail investors to pile into the
market and drive up prices.

Anxiety has grown as investors ask whether hedge funds will
need to liquidate other positions to address losses in stocks
they have shorted, said Michael Arone, chief investment
strategist at State Street Global Advisors in Boston.

"Once this short squeeze inevitably ends and there aren't
any more greater fools to bid up these stocks, will retail
investors get stuck holding the bag?" Arone asked.

"The unintended consequences of this potential volatility
have markets on edge as we end the week," Arone said.

Arone added that investors need to take a giant step back as
earnings are strong, the economy is improving, fiscal and
monetary policy is supportive and vaccines are rolling out.

MSCI's benchmark for global equity markets
fell 1.82% to 642.57, while Europe's broad FTSEurofirst 300
index closed down 1.95% at 1,524.1 to post its worst
weekly loss, at 3.3%, since October.

On Wall Street, the Dow Jones Industrial Average fell
2.03%, the S&P 500 lost 1.93% and the Nasdaq Composite
dropped 2%. The three indexes suffered their biggest
weekly fall since the end of October.

MSCI's broadest index of Asia-Pacific shares outside Japan
fell 1.1% to post a weekly loss of 4.4%. Japan's
Nikkei fell 1.9%, recording its first weekly loss of the
year.

VACCINE DISPUTE

Delays in COVID-19 vaccine production have snowballed into a
spat between Britain, the European Union and drugmakers over how
best to direct limited supplies.

AstraZeneca Plc offered eight million more doses of
its COVID-19 vaccine to the European Union after it unexpectedly
announced supply cuts last week. But the bloc said that was far
short of what was originally promised, an EU official told
Reuters on Friday.

New variants of the novel coronavirus have prolonged
lockdowns and delayed expectations of an economic rebound.

Click here http://tmsnrt.rs/2EmTD6j for an interactive chart
on the vaccine race.

The U.S. dollar retreated from its highest level since
mid-November against the Japanese yen as investors
rebalanced portfolios for month-end. The greenback slid 0.48%
against the yen and traded little changed against an index of
currencies, falling 0.002%.

Bitcoin jumped as much as 14% to a two-week high
after Tesla Inc chief Elon Musk tagged the
cryptocurrency in his Twitter biography.

French 10-year government bond yields, which
move inversely to price, rose four basis points after France's
gross domestic product contracted less than expected in the
fourth quarter of 2020.

U.S. Treasury yields rose, in line with those in Europe,
after data showed inflation perked up last month, while
employment costs rose, suggesting the world's largest economy is
on the mend from the devastating effects of the pandemic.

The U.S. yield curve steepened as long yields increased,
with the spread between 2-year and 10-year notes hitting 98.20
basis points, the widest in about a week.

The 10-year U.S. Treasury note rose 2.1 basis
points to yield 1.0757%.

Oil prices traded mixed as demand concerns caused by new
coronavirus variants and slow vaccine rollouts offset a cut in
Saudi Arabian oil supply and falling U.S. oil inventories.

Brent crude futures settled up 35 cents at $55.88 a
barrel. U.S. crude futures fell 14 cents to settle at
$52.20 a barrel.

Spot gold prices rose 0.16% to $1,843.31 an ounce.
U.S. gold futures settled up 0.5% to $1,850.30 an ounce.

(Additional reporting by Tom Westbrook in Singapore and Alwyn
Scott in New York; Editing by Will Dunham, Richard Pullin, Ana
Nicolaci da Costa, William Maclean, Larry King, Dan Grebler and
Richard Chang)

More News
Today 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
Today 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.